TABLE I.
Demographics, Treatment and Follow-Up Characteristics
| % (N) or mean (SD) | |
|---|---|
| Age, mean (SD) | 8.47 (4.92) |
| 1–4 years, % (No.) | 32.73 (109) |
| ≥5 years, % (No.) | 67.27 (224) |
| Male sex, % (No.) | 49.25 (164) |
| Diagnosis, % (No.) | |
| Hodgkin lymphoma | 35.44 (118) |
| ALL | 43.54 (145) |
| Wilm tumor | 10.21 (34) |
| Ewing sarcoma | 3.90 (13) |
| Osteosarcoma | 3.30 (11) |
| Rhabdomyosarcoma | 2.10 (7) |
| Lymphoma | 0.60 (2) |
| Undifferentiated sarcoma | 0.60 (2) |
| Angiosarcoma | 0.30 (1) |
| Doxorubicin dose (mg/m2), mean (SD)a | 212.9 (103.52) |
| Radiotherapy receipt, % (No.)b | 39.04 (130) |
| Age x Anthracycline Dose, % (No.) | 23.12 (77) |
| 1–4 years + 1–250 mg/m2 | 9.61 (32) |
| 1–4 years + ≥250 mg/m2 | 52.55 (175) |
| ≥5 + 1–250 mg/m2 | 14.71 (49) |
| ≥5 + ≥ 250 mg/m2 | 10.51 (35) |
| Any age + no anthracycline | |
| Conventional cardiac risk factors | |
| Smoking (former) | 3.3 (11) |
| Smoking (current at last follow-up) | 10.2 (34) |
| Hypertension (ever) | 3.6 (13) |
| Diabetes (ever) | 2.1 (7) |
| No. echocardiograms, mean (SD)c | 2.86 (2.10) |
a
Anthracycline drugs included doxorubicin, daunomycin, and epirubicin. Anthracycline doses were converted to doxorubicin equivalent dose by using conversion factor 0.83 for daunomycin and 0.67 for epirubicin.
b
Radiation received by the heart.
c
Number of echocardiograms received.